Applied BioCode Corporation (6598.TW)

TWD 20.35

(-0.97%)

Operating Expenses Summary of Applied BioCode Corporation

Applied BioCode Corporation's latest annual operating expenses in 2023 was 455.44 Million TWD , down -3.88% from previous year.
Applied BioCode Corporation's latest quarterly operating expenses in 2024 Q2 was 106.25 Million TWD , up 6.31% from previous quarter.
Applied BioCode Corporation reported a annual operating expenses of 426.77 Million TWD in annual operating expenses 2022, up 20.45% from previous year.
Applied BioCode Corporation reported a annual operating expenses of 354.31 Million TWD in annual operating expenses 2021, up 8.34% from previous year.
Applied BioCode Corporation reported a quarterly operating expenses of 110.24 Million TWD for 2024 Q1, up 3.35% from previous quarter.
Applied BioCode Corporation reported a quarterly operating expenses of 106.66 Million TWD for 2023 Q4, down -11.69% from previous quarter.

Annual Operating Expenses Chart of Applied BioCode Corporation (2023 - 2013)

Historical Annual Operating Expenses of Applied BioCode Corporation (2023 - 2013)

Year	Operating Expenses	Operating Expenses Growth
2023	455.44 Million TWD	-3.88%
2022	426.77 Million TWD	20.45%
2021	354.31 Million TWD	8.34%
2020	327.03 Million TWD	-0.31%
2019	328.04 Million TWD	15.26%
2018	284.61 Million TWD	4.34%
2017	272.76 Million TWD	36.75%
2016	199.46 Million TWD	-12.37%
2015	227.61 Million TWD	37.52%
2014	165.51 Million TWD	93.87%
2013	85.37 Million TWD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	106.25 Million TWD	6.31%
2024 Q1	110.24 Million TWD	3.35%
2023 Q4	106.66 Million TWD	-11.69%
2023 FY	410.23 Million TWD	-3.88%
2023 Q1	107.75 Million TWD	-4.41%
2023 Q2	108.44 Million TWD	0.64%
2023 Q3	120.78 Million TWD	11.37%
2022 FY	426.77 Million TWD	20.45%
2022 Q1	97.32 Million TWD	-2.38%
2022 Q4	112.73 Million TWD	0.19%
2022 Q3	112.51 Million TWD	7.98%
2022 Q2	104.19 Million TWD	7.06%
2021 Q4	99.7 Million TWD	11.15%
2021 Q2	84.28 Million TWD	4.54%
2021 Q1	80.62 Million TWD	-3.66%
2021 FY	354.31 Million TWD	8.34%
2021 Q3	89.69 Million TWD	6.42%
2020 FY	327.03 Million TWD	-0.31%
2020 Q4	83.68 Million TWD	2.03%
2020 Q3	82.02 Million TWD	-6.85%
2020 Q2	88.05 Million TWD	20.16%
2020 Q1	73.27 Million TWD	8.63%
2019 Q3	83.25 Million TWD	-0.92%
2019 FY	328.04 Million TWD	15.26%
2019 Q1	93.25 Million TWD	25.6%
2019 Q2	84.03 Million TWD	-9.89%
2019 Q4	67.45 Million TWD	-18.98%
2018 Q2	65.56 Million TWD	0.0%
2018 FY	284.61 Million TWD	4.34%
2018 Q4	74.24 Million TWD	-6.56%
2018 Q3	79.46 Million TWD	21.2%
2018 Q1	65.56 Million TWD	2.94%
2017 Q3	63.69 Million TWD	-12.62%
2017 Q2	72.89 Million TWD	0.0%
2017 Q4	63.69 Million TWD	0.0%
2017 Q1	72.89 Million TWD	0.0%
2017 FY	272.76 Million TWD	36.75%
2016 Q4	- TWD	0.0%
2016 Q2	47.85 Million TWD	0.0%
2016 FY	199.46 Million TWD	-12.37%
2015 FY	227.61 Million TWD	37.52%
2015 Q4	- TWD	0.0%
2014 FY	165.51 Million TWD	93.87%
2013 FY	85.37 Million TWD	0.0%

Peer Operating Expenses Comparison of Applied BioCode Corporation

Name	Operating Expenses	Operating Expenses Difference
Excelsior Medical Co., Ltd.	919.21 Million TWD	50.453%
Apex Medical Corp.	944.09 Million TWD	51.759%
OK Biotech Co., Ltd.	216.37 Million TWD	-110.489%